Haemwill (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemwill is indicated for the management of bleeding disorders that involve deficiency of factor VIII and von Willebrand factor.

• On‑demand treatment of acute bleeding episodes in patients with hemophilia A.
• Routine prophylaxis to reduce the frequency of spontaneous joint and muscle bleeds in hemophilia A.
• Treatment of bleeding episodes associated with von Willebrand disease types 1, 2, and 3.
• Perioperative management to maintain hemostasis during surgical or dental procedures in affected individuals.
• Use in patients undergoing major trauma when rapid factor replacement is required.

Adverse reactions reported with Haemwill reflect the typical safety profile of plasma‑derived clotting factor concentrates.

Common

• Mild infusion‑site reactions such as erythema, warmth, or tenderness.
• Transient fever or chills occurring during or shortly after administration.
• Headache or fatigue reported in a minority of patients.
• Nausea or vomiting.

Serious

• Development of inhibitors (neutralizing antibodies) against factor VIII or von Willebrand factor.
• Allergic or anaphylactic reactions, including urticaria, bronchospasm, or hypotension.
• Thrombotic events such as deep‑vein thrombosis or pulmonary embolism, particularly with high‑dose regimens.
• Transmission of infectious agents, although risk is minimized by viral inactivation steps.

When prescribing Haemwill, clinicians should consider several precautionary measures to ensure safe and effective use.

• Assess baseline inhibitor status; patients with existing inhibitors may have reduced efficacy.
• Monitor for signs of allergic reactions during the first infusion and with subsequent doses.
• Evaluate cardiovascular risk, as high factor levels can increase thrombosis potential.
• Use caution in patients with a history of thromboembolic disease or recent major surgery.
• Perform regular viral safety testing of the product batch as required by regulatory authorities.
• Adjust dosing in pediatric patients based on weight and clinical response.

Haemwill may interact with other medications that affect hemostasis or immune response.

Avoid

• Concurrent use of other clotting factor concentrates without medical supervision, which can increase thrombotic risk.
• Administration of pro‑coagulant agents such as activated prothrombin complex concentrates in the same treatment episode.

Use with caution

• Antifibrinolytic drugs (e.g., tranexamic acid) may enhance hemostatic effect and should be coordinated.
• Immunosuppressive therapies that could alter inhibitor development.
• High‑dose corticosteroids, which may mask early signs of allergic reactions.
• Concomitant use of investigational gene‑therapy products targeting factor VIII.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that affect platelet function.